PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1377)
Related Products (1377)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
VHL-SNAP2-5C
0 ImagesCat. No.: HY-175417Purity: 99.98%VHL-SNAP2-5C is a PROTAC degrader targeting SNAP-tag fusion proteins, with an IC50 of 0.33 μM for binding to VHL. VHL-SNAP2-5C covalently binds to the SNAP-tag target at one end and recruits the VHL ubiquitin E3 ligase at the other end to form a ternary complex, thereby inducing proteasome-dependent ubiquitination and degradation of SNAP fusion proteins through its heterobifunctional structure. VHL-SNAP2-5C can be used in studies of protein homeostasis and degradation mechanisms.
-
KT-474 hydrochloride
0 ImagesSynonyms: KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride
-
SS47 TFA
0 ImagesCat. No.: HY-146231APurity: 99.55%SS47 TFA is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 TFA promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 TFA also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 TFA can be used in breast cancer-related research.
-
PROTAC GPX4 degrader-4
0 ImagesPROTAC GPX4 degrader-4 is a potent GPX4 PROTAC degrader, with DC50 values of 1366.67 nM and 475.15 nM in T24 and RT4 cells, respectively. PROTAC GPX4 degrader-4 targets and degrades GPX4 protein via the ubiquitin-proteasome system, thereby inducing cellular ferroptosis. PROTAC GPX4 degrader-4 can be used for research on bladder cancer.
-
WH-10417-099
0 ImagesWH-10417-099 is a CRBN-based PROTAC multi-kinase degrader that induces the degradation of the maximum number of unique kinases (over 125 unique kinases, such as CSNK1E and PI3Kγ) simultaneously. WH-10417-099 induces protein degradation via the ubiquitin biotinylation (E-STUB) pathway, exhibits synergistic effects with SB-405483 (HY-W1135319). The E3 ligase ligand and linker of WH-10417-099 can form the conjugate Pomalidomide 4'-PEG5-acid (HY-131647).
-
Omtebrutideg
0 ImagesSynonyms: PROTAC BTK Degrader-10Omtebrutideg (PROTAC BTK Degrader-10) (Example 1P) is a PROTAC degrader for BTK. Omtebrutideg can be used for research of chronic lymphocytic leukemia (CLL).
-
ZXH-4-130
0 ImagesZXH-4-130 is a potent and selective Cereblon (CRBN) degrader. ZXH-4-130 recruits the VHL E3 ligase to specifically target CRBN as a substrate for selective degradation as a hetero-PROTAC molecule. ZXH-4-130 can be applied in studies on the biological functions of CRBN and related research of frontotemporal dementia.
-
α1A-AR Degrader 9c
0 ImagesCat. No.: HY-147100CAS No.: 2863635-02-1α1A-AR Degrader 9c is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC50 of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC50 of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research.
-
PROTAC PARP2 degrader-1
0 ImagesCat. No.: HY-183013CAS No.: 2925182-32-5PROTAC PARP2 degrader-1 is an orally active PARP2 PROTAC degrader with a DC50 of 2 μM. PROTAC PARP2 degrader-1 potently inhibits the enzymatic activities of PARP1 (IC50 = 2.74 nM) and PARP2 (IC50 = 0.32 nM), with approximately 10-fold higher selectivity for PARP2. PROTAC PARP2 degrader-1 induces cell cycle arrest and apoptosis, and exhibits significant anti-tumor efficacy in mouse models. PROTAC PARP2 degrader-1 can be used for the research of triple-negative breast cancer.
-
PROTAC erf3a Degrader-1
0 ImagesPROTAC erf3a Degrader-1 (Compound C63) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-1 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-1 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer.
-
BT-O2C
0 ImagesBT-O2C is a p300 PROTAC degrader. BT-O2C induces p300 degradation via proteasome- and ubiquitin-like modification-dependent pathways, downregulates the expression of CIC::DUX4 sarcoma target genes, and exerts cytotoxicity against such sarcoma cells. BT-O2C can be used in CIC::DUX4 sarcoma-related studies.
-
PPM-3
0 ImagesCat. No.: HY-149616CAS No.: 3032388-42-1PPM-3 is a highly selective ERK5 PROTAC degrader that mediates the degradation of ERK5 protein by recruiting VHL. PPM-3 inhibits ERK5 kinase activity with an IC50 of 62.4 nM. PPM-3-mediated ERK5 degradation exhibits a hook effect. PPM-3 exerts no significant direct inhibitory effect on the proliferation and migration of cancer cells. PPM-3 can be used in studies related to macrophage polarization and tumor immunity.
-
AZ'3137
0 ImagesAZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader with a DC50 value of 22 nM. AZ‘3137 can degrade L702H mutant AR (DC50 of 92 nM). AZ'3137 can inhibit cell proliferation of LNCaP, with a GI50 value of 74 nM. AZ'3137 can inhibit AR signaling and tumor growth in prostate cancer mice.
-
TAT-PiET-PROTAC
0 ImagesTAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445), which is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET-PROTAC can be used for the research of cancer, such as breast cancer.
